A detailed history of Charles Schwab Investment Management Inc transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 125,845 shares of CABA stock, worth $261,757. This represents 0.0% of its overall portfolio holdings.

Number of Shares
125,845
Previous 118,327 6.35%
Holding current value
$261,757
Previous $885,000 32.99%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$3.94 - $8.24 $29,620 - $61,948
7,518 Added 6.35%
125,845 $593,000
Q2 2024

Aug 12, 2024

BUY
$7.22 - $18.82 $179,070 - $466,773
24,802 Added 26.52%
118,327 $885,000
Q1 2024

May 08, 2024

SELL
$16.79 - $25.38 $46,760 - $70,683
-2,785 Reduced 2.89%
93,525 $1.6 Million
Q4 2023

Feb 06, 2024

BUY
$12.21 - $23.36 $3,724 - $7,124
305 Added 0.32%
96,310 $2.19 Million
Q3 2023

Nov 08, 2023

BUY
$11.84 - $18.65 $325,079 - $512,054
27,456 Added 40.05%
96,005 $1.46 Million
Q2 2023

Aug 09, 2023

BUY
$7.65 - $13.95 $447,303 - $815,670
58,471 Added 580.18%
68,549 $884,000
Q4 2022

Feb 13, 2023

BUY
$0.64 - $9.3 $6,449 - $93,725
10,078 New
10,078 $93,000
Q2 2021

Aug 16, 2021

SELL
$7.2 - $11.73 $233,208 - $379,934
-32,390 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$9.81 - $15.8 $16,833 - $27,112
1,716 Added 5.59%
32,390 $405,000
Q3 2020

Nov 13, 2020

SELL
$9.71 - $14.41 $17,759 - $26,355
-1,829 Reduced 5.63%
30,674 $333,000
Q2 2020

Aug 14, 2020

BUY
$6.39 - $11.28 $88,852 - $156,848
13,905 Added 74.77%
32,503 $363,000
Q1 2020

May 15, 2020

BUY
$6.0 - $18.67 $28,200 - $87,749
4,700 Added 33.82%
18,598 $136,000
Q4 2019

Feb 07, 2020

BUY
$7.88 - $17.71 $109,516 - $246,133
13,898 New
13,898 $195,000

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $60.3M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.